Table 1 HIV-1 vaccine regimen and dosing schedules.

From: Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans

	Protocol	Arm	VAC1	VAC2	VAC3	VAC4	Env	Specimens Analyzed
DNA/vector	HVTN 076 NCT00955006	T1	DNA	DNA	DNA	Ad5	gp140	CS (n = 6) Saliva (n = 16) SP (n = 10)
	HVTN 086 NCT01418235	T3	DNA + placebo	DNA	MVA + placebo	MVA + placebo	gp150	CS (n = 4) RS (n = 7)
	HVTN 205 NCT00820846	T1 + T3	DNA	DNA	MVA	MVA	gp160, gp150	CS (n = 6) RS (n = 7) SP (n = 9)
DNA/vector + protein	HVTN 086 NCT01418235	T1	MVA + placebo	MVA	gp140/MF59 + placebo	gp140/MF59 + placebo	gp150, gp140	CS (n = 9) RS (n = 9)
		T4	DNA + placebo	DNA	MVA + gp140/MF59	MVA + gp140/MF59	gp150, gp140	CS (n = 9) RS (n = 5)
		T1	NYVAC + placebo	NYVAC + placebo	NYVAC + AIDSVAX® B/E	NYVAC + AIDSVAX® B/E	gp140, gp120	CS (n = 6) RS (n = 9) Saliva (n = 19) SP (n = 10)
	HVTN 096 NCT01799954	T2	NYVAC + AIDSVAX® B/E	NYVAC + AIDSVAX® B/E	NYVAC + AIDSVAX® B/E	NYVAC + AIDSVAX® B/E	gp140, gp120	CS (n = 2) RS (n = 7) Saliva (n = 19) SP (n = 6)
		T3	DNA-HIV-PT123 + placebo	DNA-HIV-PT123 + placebo	NYVAC + AIDSVAX® B/E	NYVAC + AIDSVAX® B/E	gp140, gp120	CS (n = 3) RS (n = 7) Saliva (n = 17) SP (n = 7)
		T4	DNA-HIV-PT123 + AIDSVAX® B/E	DNA-HIV-PT123 + AIDSVAX® B/E	NYVAC + AIDSVAX® B/E	NYVAC + AIDSVAX® B/E	gp140, gp120	CS (n = 6) RS (n = 9) Saliva (n = 19) SP (n = 5)
	HVTN 097 NCT02109354	T1^a	ALVAC	ALVAC	ALVAC + AIDSVAX® B/E	ALVAC + AIDSVAX® B/E	gp120	CS (n = 7) RS (n = 18) SP (n = 10)
		T2	ALVAC	ALVAC	ALVAC + AIDSVAX® B/E	ALVAC + AIDSVAX® B/E	gp120	CS (n = 4) RS (n = 6) SP (n = 4)
Protein only	HVTN 088 NCT01376726	T1^b	gp140/MF59	gp140/MF59	gp140/MF59	–	gp140^b	CS (n = 5) RS (n = 10) Saliva (n = 16) SP (n = 7)
		T2	gp140/MF59	gp140/MF59	gp140/MF59	–	gp140	CS (n = 1) RS (n = 10) Saliva (n = 20) SP (n = 10)
Vector only	HVTN 205 NCT00820846	T4	MVA	MVA	Placebo	MVA	gp150	CS (n = 11) RS (n = 7) SP (n = 27)

Immunization regimens are shown for HVTN 076, 088, 086, 096, 097, and 205. Vaccine regimens were classified into four types (1–4), as indicated.
CS cervical sponge, RS rectal sponge, SP seminal plasma.
^aParticipants in HVTN 097 group T1 received also received Tetanus toxoid vaccine (Tetavax®) 1 month prior to initiation of the HIV vaccine administration schedule, and Hepatitis B vaccine (ENGERIX-B®) 2 weeks following the final HIV vaccine administration.
^bParticipants in HVTN 088 group T1 (primed) include previously vaccinated participants from HVTN 049 who received a DNA prime + gp140 protein boost, and participants from AVEG trials who received a vector prime and vector + gp120 protein boost. For the analyses in this manuscript, all previously vaccinated participants are categorized in the protein boost the only group, due to the long rest interval between immunizations.

Back to article page

Table 1 HIV-1 vaccine regimen and dosing schedules.

Search

Quick links